Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California 94110, USA.
J Biol Chem. 2011 Jul 15;286(28):24581-92. doi: 10.1074/jbc.M111.248021. Epub 2011 May 20.
Certain ritonavir resistance mutations impair HIV infectivity through incomplete Gag processing by the mutant viral protease. Analysis of the mutant virus phenotype indicates that accumulation of capsid-spacer peptide 1 precursor protein in virus particles impairs HIV infectivity and that the protease mutant virus is arrested during the early postentry stage of HIV infection before proviral DNA synthesis. However, activation of the target cell can rescue this defect, implying that specific host factors expressed in activated cells can compensate for the defect in ritonavir-resistant HIV. This ability to rescue impaired HIV replication presented a unique opportunity to identify host factors involved in postentry HIV replication, and we designed a functional genetic screen so that expression of a given host factor extracted from activated T cells would lead directly to its discovery by rescuing mutant virus replication in nonactivated T cells. We identified the cellular heat shock protein 90 kDa α (cytosolic), class B member 1 (HSP90AB1) as a host factor that can rescue impaired replication of ritonavir-resistant HIV. Moreover, we show that pharmacologic inhibition of HSP90AB1 with 17-(allylamino)-17-demethoxygeldanamycin (tanespimycin) has potent in vitro anti-HIV activity and that ritonavir-resistant HIV is hypersensitive to the drug. These results suggest a possible role for HSP90AB1 in postentry HIV replication and may provide an attractive target for therapeutic intervention.
某些利托那韦耐药突变会通过突变病毒蛋白酶不完全加工 Gag 来损害 HIV 的感染力。对突变病毒表型的分析表明,衣壳-间隔肽 1 前体蛋白在病毒颗粒中的积累会损害 HIV 的感染力,并且蛋白酶突变病毒在 HIV 感染的早期进入后阶段被阻断,在原病毒 DNA 合成之前。然而,靶细胞的激活可以挽救这种缺陷,这意味着在激活的细胞中表达的特定宿主因子可以补偿利托那韦耐药 HIV 的缺陷。这种拯救受损 HIV 复制的能力为鉴定参与进入后 HIV 复制的宿主因子提供了一个独特的机会,我们设计了一个功能遗传筛选,以便从激活的 T 细胞中提取的特定宿主因子的表达将直接通过在非激活的 T 细胞中拯救突变病毒复制来发现。我们确定了细胞热休克蛋白 90 kDa α(细胞质),B 类成员 1(HSP90AB1)作为一种宿主因子,可以拯救利托那韦耐药 HIV 的受损复制。此外,我们表明,用 17-(烯丙基氨基)-17-去甲氧基格尔德霉素(坦那西普霉素)抑制 HSP90AB1 的药理作用具有很强的体外抗 HIV 活性,并且利托那韦耐药 HIV 对该药物高度敏感。这些结果表明 HSP90AB1 可能在后进入 HIV 复制中发挥作用,并可能为治疗干预提供有吸引力的目标。